UNSPSC 51272207: Ketamine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C13H16ClNO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O18YUO0I83, chemically known as cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8ci) but more generally known as ketamine hydrochloride, which bears US NIH Compound Identifier 3821. European Medicines Agency schedules Ketamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02830MIG.

Most nations, for tariff and trade purposes, schedule ketamine hydrochloride under HS 29223900. As of Q4 2014, KETAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ketamine hydrochloride bears US NLM identifiers UMLS ID C0700541 and NCI Concept Code C29142. SMILES: CNC1(CCCCC1=O)C2CCCCC2CL.CL.

UNSPSC 51272207 Ketamine hydrochloride, a Commodity code, nominally addresses a specific pharmaceutical product, but recent state and local activity under this code shows minimal direct procurement of ketamine itself. Instead, the tagged opportunities reflect broader pharmaceutical supply contracting that encompasses generic drugs, over-the-counter products, and harm-reduction medications such as naloxone. State and local governments are buying pharmaceuticals through cooperative purchasing alliances and direct health department acquisitions, with issuing bodies including county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance). The work solicited ranges from manufacturer agreements for generic multi-source drugs and OTC products distributed through authorized wholesalers, to direct procurement of naloxone for community health initiatives, to exploratory requests for information on direct-to-manufacturer prescription programs.

Geographic activity centers on Minnesota (via MMCAP, which serves multiple states including Oregon), Texas, and Florida, with the cooperative purchasing structure extending the reach across state lines. A representative opportunity is Seminole County's IFB60459723LAS (due July 26, 2026), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the County Community Health Building, with a two-year initial term and one-year renewal option. The Minnesota MMCAP RFP (due March 26, 2026) establishes multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, weighted 75 percent on price competitiveness and requiring vendors to maintain relationships with at least two of the three wholesalers. Texas HHS issued an exploratory RFI in April 2026 on direct-to-manufacturer prescription programs, signaling state interest in alternative contracting models outside traditional pharmacy benefit manager arrangements. Vendors pursuing this code should focus on cooperative purchasing capability, wholesaler integration, cGMP and Drug Supply Chain Security Act compliance, and naloxone or harm-reduction product supply chains.